Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA.
Am Heart J. 2010 Jun;159(6):1074-80. doi: 10.1016/j.ahj.2010.03.023.
Data from longitudinal studies suggest that biomarkers of inflammation and endothelial dysfunction are associated with development of hypertension. None of these studies have examined the association of these markers with hypertension risk in persons with diabetes. We examined the associations of inflammatory and endothelial dysfunction markers with long-term hypertension incidence in persons with type 1 diabetes mellitus.
The 15-year cumulative incidence of hypertension was measured in Wisconsin Epidemiologic Study of Diabetic Retinopathy participants (n = 795). Hypertension was defined as a systolic blood pressure > or =140 mm Hg and/or a diastolic blood pressure > or =90 mm Hg and/or history of current antihypertensive treatment. We measured serum high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1, and serum total homocysteine as "novel" markers of hypertension development. The relation of risk factors to hypertension incidence was determined using a proportional hazards approach with discrete linear logistic regression modeling.
After controlling for age, gender, diabetes duration, body mass index, glycosylated hemoglobin, baseline systolic and diastolic blood pressure, proteinuria, and chronic kidney disease status, sVCAM-1 was significantly related to higher odds of developing incident hypertension (odds ratio per log sVCAM-1 1.95, 95% CI 1.01-3.74). None of the other markers of inflammation and endothelial dysfunction were related to incident hypertension in the cohort.
Our data showed that sVCAM-1 as a marker of endothelial dysfunction was the strongest predictor of hypertension risk in individuals with type 1 diabetes. This association was independent of the presence of diabetic nephropathy.
纵向研究的数据表明,炎症和内皮功能障碍的生物标志物与高血压的发展有关。这些研究中没有一项研究检查这些标志物与糖尿病患者的高血压风险之间的关系。我们研究了炎症和内皮功能障碍标志物与 1 型糖尿病患者长期高血压发病率之间的关系。
威斯康星州糖尿病视网膜病变研究参与者(n = 795)测量了 15 年高血压累积发病率。高血压定义为收缩压>或=140mmHg 和/或舒张压>或=90mmHg 和/或正在接受抗高血压治疗的病史。我们测量了血清高敏 C 反应蛋白、白细胞介素-6、肿瘤坏死因子-α、可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性细胞间黏附分子-1 和血清总同型半胱氨酸作为高血压发展的“新型”标志物。使用比例风险方法和离散线性逻辑回归模型确定危险因素与高血压发病率的关系。
在控制年龄、性别、糖尿病病程、体重指数、糖化血红蛋白、基线收缩压和舒张压、蛋白尿和慢性肾脏病状态后,sVCAM-1 与发生高血压的几率显著相关(每对数 sVCAM-1 升高 1.95,95%可信区间 1.01-3.74)。炎症和内皮功能障碍的其他标志物与该队列中的高血压发病率均无相关性。
我们的数据表明,sVCAM-1 作为内皮功能障碍的标志物是 1 型糖尿病患者高血压风险的最强预测因子。这种相关性独立于糖尿病肾病的存在。